



Universiteit  
Leiden  
The Netherlands

## **Innovation in cholinergic enhancement for Alzheimer's Disease**

Baakman, A.C.

### **Citation**

Baakman, A. C. (2021, November 17). *Innovation in cholinergic enhancement for Alzheimer's Disease*. Retrieved from <https://hdl.handle.net/1887/3240157>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3240157>

**Note:** To cite this publication please use the final published version (if applicable).

## CURRICULUM VITAE

---

Anne Catrien Baakman was born on January 11th 1983 in Vollenhove. She completed secondary school (gymnasium) at the Revis Lyceum in Doorn in 2001 and commenced medical school at University Utrecht in the same year. As a third-year student, she represented the students' interests as member of the management team of the Faculty of Medicine. She was also actively involved in workgroup Gamma, which organised lectures on medical topics that were not covered as part of the core curriculum. For her internships in gynaecology and ophthalmology, she travelled to South Africa and lived in Pretoria for 3 months. During her studies, Anne Catrien held part-time jobs as a teaching assistant in statistics and epidemiology and at the clinical pharmacology unit of Kende, a contract research organisation for early phase clinical pharmacology trials in healthy volunteers. After graduating as medical doctor in June 2009, Anne Catrien worked as a physician at the neurology departments of the University Medical Centre in Utrecht and the Elisabeth-TweeSteden Hospital in Tilburg. In December 2010, she was appointed as a project leader and research physician at the neurology group of the Centre for Human Drug Research in Leiden. She contributed to several clinical trials, which were supervised by professor Groeneveld and professor van Gerven, focussing on procognitive compounds and anticholinergic pharmacological challenges. For the galantamine trial, there was a close collaboration with the Alzheimer Center of the Amsterdam UMC. She presented her work at several neurological and pharmacological conferences, including the Alzheimer's Association International Conference and the conference of the British Pharmacological Society. Anne Catrien began her resident training in neurology, supervised by professor Berendse, at the VU Medical Centre in Amsterdam in July 2016. She lives in Laren with her husband Jarmil and their three children: Stijn, Julia and Olivier.

## LIST OF PUBLICATIONS

---

- Baakman AC**, Alvarez-Jimenez R, Loewen G, de Kam ML, Broekhuizen K, Hilt DC, Groeneveld GJ. No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model. *Alzheimers Dement (NY)*. 2019 Apr 1;5:89-98.
- Baakman AC**, Zuiker R, van Gerven JMA, Gross N, Yang R, Fetell M, Gershon A, Gilgun-Sherki Y, Hellriegel E, Spiegelstein O. Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers. *Br J Clin Pharmacol*. 2019 May;85(5):970-985.
- Baakman AC**, Alvarez-Jimenez R, Rissmann R, Klaassen ES, Stevens J, Goulooz SC, den Burger JCG, Swart EL, van Gerven JMA, Groeneveld GJ. An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine. *Br J Clin Pharmacol*. 2017 Aug;83(8):1676-1687.
- van Amerongen G, Kanhai K, **Baakman AC**, Heuberger J, Klaassen E, Beumer TL, Strijers RLM, Killestein J, van Gerven J, Cohen A, Groeneveld GJ. Effects on Spasticity and Neuropathic Pain of an Oral Formulation of  $\Delta$ 9-tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis. *Clin Ther*. 2018 Sep;40(9):1467-1482.
- Alvarez-Jimenez R, **Baakman AC**, Stevens J, Goulooz SC, Hart EP, Rissmann R, van Gerven JM, Groeneveld GJ. Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation. *J Psychopharmacol*. 2017 Feb;31(2):192-203. doi: 10.1177/0269881116681417. Epub 2016 Dec 9. PMID: 27927703.
- Alvarez-Jimenez R, Groeneveld GJ, van Gerven JM, Goulooz SC, **Baakman AC**, Hay JL, Stevens J. Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects. *Br J Clin Pharmacol*. 2016 Oct;82(4):1011-21.
- Baakman AC**, 't Hart E, Kay DG, Stevens J, Klaassen ES, Maelicke A, Groeneveld GJ. First in human study with a prodrug of galantamine: Improved benefit-risk ratio? *Alzheimers Dement (NY)*. 2016 Jan 20;2(1):13-22.
- Verberne WR, Snijders TJ, Liem KS, **Baakman AC**, Veldhuijzen DS. Toepassingen van sensibiliteitsonderzoek met 'quantitative sensory testing' [Applications of 'quantitative sensory testing']. *Ned Tijdschr Geneeskd*. 2013;157(5):A5434. Dutch.

